查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401926

到 2030 年全球标靶治疗市场预测：按类型、癌症类型、给药途径、配销通路、最终用户和地区进行分析

Targeted Cancer Therapy Market Forecasts to 2030 - Global Analysis By Type, By Cancer Type, By Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球标靶癌症治疗市场规模为 761 亿美元，预计预测期内复合年增长率为 8.8%，到 2030 年将达到 1,374 亿美元。

标靶癌症治疗是一种精准医学方法，使用药物和其他物质来特异性识别和攻击癌细胞，同时最大限度地减少对健康细胞的损害。这种方法旨在抑制癌细胞的生长和存活，并且通常比传统化疗具有更少的副作用。

据美国癌症协会称，2019 年美国预计将诊断出约 170 万新癌症病例。同样，根据美国国家癌症研究所的数据，2018 年，美国约有 1,735,350 人新诊断出癌症，609,640 人死于癌症。

全球癌症发生率增加

人们越来越需要更有效、更有针对性的治疗方法。标靶癌症治疗精确地解决导致癌症进展的特定分子或遗传异常，从而改善治疗结果。各种癌症类型的负担日益增加，加上对癌症遗传基础了解的进步，正在推动标靶治疗的开发和采用。这一背景凸显了开发创新和个体化治疗方法的迫切需要，以及在面对癌症发病率不断增加和多样化的情况下，全球医疗保健迫切需要改善癌症治疗和结果。符合要求。

与标靶治疗相关的经济负担

虽然这些治疗方法提供了准确有效的治疗，但其高昂的成本往往会对负担能力和可近性带来挑战。标靶抗癌药物的研发和生产流程复杂，研究投入大，价格昂贵。此外，对持续监测、分子检测和个体化治疗计划的需求增加了患者和医疗保健系统的总体经济负担。与标靶治疗相关的费用可能会限制某些患者群体的获得性治疗，引发人们对医疗保健差异的担忧。

癌症研究的支持政策与资金

世界各地的政府和医疗机构越来越认识到标靶治疗彻底改变癌症治疗的潜力。透过资金和支持政策促进研究、开发和临床试验的努力正在创造有利于创新的环境。此类财政支持加速了新型标靶治疗的发现，加快了监管核准，并改善了市场准入。在雄厚资金的支持下，公私合作伙伴关係不仅能推动科学进步，还能确保前沿的标靶治疗癌症治疗更快地到达患者手中，解决未满足的医疗需求，并为癌症治疗的发展做出贡献。

与标靶治疗相关的副作用

儘管这些治疗方法的目的是精确攻击癌细胞，但脱靶效应和意想不到的后果可能会导致副作用。接受标靶治疗的患者可能会出现疲劳、皮肤反应、胃肠道失调和免疫相关併发症等副作用。此外，标靶治疗的潜在抗药性和长期影响仍然令人担忧。副作用不仅影响患者的生活质量，还可能导致治疗中断。

COVID-19 的影响：

COVID-19大流行对市场产生了重大影响。医疗保健系统的中断、资源的重新优先排序以及临床试验的延迟正在阻碍标靶治疗的开发和可用性。患者的焦虑和后勤的挑战也影响着治疗的医嘱遵从性。然而，这场大流行凸显了创新治疗方法的重要性，并加速了远端医疗和数位健康解决方案在癌症护理中的采用。

乳癌领域预计在预测期内规模最大

乳癌领域预计将出现良好的成长。乳癌的标靶治疗包括旨在解决特定分子特征的药物，例如 HER2 抑制剂和 CDK4/6 抑制剂。与传统治疗方法相比，这些治疗方法副作用较少，疗效也较高。乳癌标靶治疗的进展凸显了我们对个人化医疗的承诺，提供更个体化、更有效的治疗选择，特别是针对HER2阳性和荷尔蒙受体阳性乳癌亚型的患者，这就是我们所提供的。

预计医院业在预测期内复合年增长率最高。

预计医院产业在预测期内将以最快的复合年增长率成长。医院为患者诊断、治疗计划和提供标靶治疗提供关键基础设施。医院拥有专门的肿瘤科和多学科团队，帮助患者获得尖端的标靶癌症治疗。此外，医院正在为临床试验、合作研究和个体化癌症治疗的整体进步做出贡献，使其成为不断发展的标靶治疗介入领域的核心参与者。

占有率最大的地区：

预计北美标靶癌症治疗市场在预测期内将继续占据大部分市场占有率。该地区强大的製药业和支持性的法规环境促进了创新标靶治疗的开发和采用。此外，学术界、研究机构和生物製药公司之间的合作正在促进精准医疗方法的快速发展。北美仍然是临床试验的重要中心，推动个体化癌症治疗的进步并影响标靶癌症治疗的全球趋势。

复合年增长率最高的地区：

预计亚太地区在预测期内复合年增长率最高。癌症发生率增加、医疗保健意识提高以及个人化医疗的进步等因素正在促进市场扩张。中国、日本和印度等国家正在进行紧张的研究和开发，以促进标靶治疗的引入。亚太地区拥有完善的医疗基础设施和完善的法规环境，使其成为创新标靶癌症治疗的开发、商业化和采用的重要中心。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球标靶治疗市场：按类型

  • 单株抗体
  • 利妥昔单抗
  • 低分子
  • 胺基酸
  • 免疫毒素
  • 白喉毒素 (DT)
  • 假单胞菌外毒素
  • 其他的

第六章全球标靶治疗市场：依癌症类型

  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 血癌
  • 妇科癌症
  • 其他的

第七章全球标靶治疗市场：依给药途径

  • 口服
  • 胃肠外的
  • 其他的

第八章全球标靶治疗市场：依配销通路

  • 医院药房
  • 线上药房
  • 零售药房

第九章全球标靶治疗市场：依最终用户分类

  • 医院
  • 癌症与放射治疗中心
  • 专科诊所
  • 其他的

第十章全球标靶治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Abbott
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC.
  • Novartis AG
  • Aurobindo Pharma
  • Mirati Therapeutics, Inc
  • Bayer AG
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Hikma Pharmaceuticals PLC
  • ImmunoGen, Inc
Product Code: SMRC24446

According to Stratistics MRC, the Global Targeted Cancer Therapy Market is accounted for $76.1 billion in 2023 and is expected to reach $137.4 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Targeted cancer therapy is a precision medicine approach that involves using drugs or other substances to specifically identify and attack cancer cells while minimizing damage to healthy cells. This method aims to disrupt the growth and survival of cancer cells, often resulting in fewer side effects compared to traditional chemotherapy.

According to the American Cancer Society reports nearly 1.7 million new cancer cases are expected to be diagnosed in 2019 in the U.S. Similarly, according to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer were diagnosed in U.S. and 609,640 people died from the disease.

Market Dynamics:

Driver:

Increasing global cancer prevalence

There is a growing need for more effective and targeted treatment approaches. Targeted Cancer Therapy offers precision in addressing specific molecular and genetic aberrations driving cancer, leading to enhanced therapeutic outcomes. The rising burden of diverse cancer types, coupled with advancements in understanding the genetic basis of cancers, propels the development and adoption of targeted therapies. This driver underscores the urgency to develop innovative and personalized treatment options, aligning with the global healthcare imperative to improve cancer care and outcomes in the face of a rising and diverse cancer landscape.

Restraint:

Financial burden associated with targeted therapies

These therapies offer precise and effective treatments, their high costs often create challenges in terms of affordability and accessibility. The development and production of targeted cancer drugs involve complex processes and substantial research investments, leading to elevated pricing. Additionally, the need for ongoing monitoring, molecular testing, and personalized treatment plans contribute to the overall financial strain on patients and healthcare systems. The expense associated with targeted therapies may limit access for certain patient populations, raising concerns about healthcare disparities.

Opportunity:

Supportive policies and funding for cancer research

Governments and healthcare organizations worldwide are increasingly recognizing the potential of targeted therapies in revolutionizing cancer treatment. Initiatives that foster research, development, and clinical trials through funding and supportive policies create an environment conducive to innovation. This financial backing accelerates the discovery of novel targeted therapies, expedites regulatory approvals, and enhances market accessibility. The collaboration between public and private sectors, backed by robust funding, not only propels scientific advancements but also ensures that cutting-edge targeted cancer therapies can reach patients more swiftly, addressing unmet medical needs and contributing to the evolution of cancer care.

Threat:

Adverse effects associated with targeted therapies

While these therapies aim for precision in attacking cancer cells, off-target effects and unintended consequences may lead to adverse reactions. Patients undergoing targeted therapy may experience side effects such as fatigue, skin reactions, gastrointestinal issues, and immune-related complications. Additionally, the potential for resistance to targeted drugs and long-term effects remains a concern. Adverse effects not only impact the quality of life for patients but may also result in treatment discontinuation.

COVID-19 Impact:

The COVID-19 pandemic has significantly impacted the market. Disruptions in healthcare systems, reprioritization of resources, and delays in clinical trials have hindered the development and accessibility of targeted therapies. Patient concerns and logistical challenges have affected treatment adherence. However, the pandemic has underscored the importance of innovative therapies, accelerating the adoption of telemedicine and digital health solutions in cancer care.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is expected to have a lucrative growth. Targeted therapies for breast cancer include drugs like HER2 inhibitors and CDK4/6 inhibitors, aiming to address specific molecular characteristics. These therapies offer improved efficacy with fewer side effects compared to conventional treatments. The evolving landscape of targeted therapies for breast cancer underscores the commitment to personalized medicine, providing more tailored and effective treatment options for patients, particularly those with HER2-positive or hormone receptor-positive breast cancer subtypes.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. They provide a crucial infrastructure for patient diagnosis, treatment planning, and the delivery of targeted therapies. With specialized oncology departments and multidisciplinary teams, hospitals facilitate patient access to cutting-edge targeted cancer therapies. Additionally, hospitals contribute to clinical trials, research collaborations, and the overall advancement of personalized cancer care, making them central to the evolving landscape of targeted therapy interventions.

Region with largest share:

During the forecast period, it is expected that the North American Targeted Cancer Therapy market will continue to hold a majority of the market share. The region's robust pharmaceutical industry and supportive regulatory environment foster the development and adoption of innovative targeted therapies. Additionally, collaborations between academia, research institutions, and biopharmaceutical companies contribute to the rapid evolution of precision medicine approaches. North America continues to be a key hub for clinical trials, driving advancements in personalized cancer treatment and influencing global trends in the Targeted Cancer Therapy landscape.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. Factors such as increasing cancer incidence, rising healthcare awareness, and advancements in personalized medicine contribute to market expansion. Countries like China, Japan, and India are witnessing significant research and development activities, fostering the adoption of targeted therapies. The region's evolving healthcare infrastructure and supportive regulatory environments position Asia Pacific as a key hub for the development, commercialization, and adoption of innovative targeted cancer treatments.

Key players in the market:

Some of the key players in Targeted Cancer Therapy market include Abbott, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Novartis AG, Aurobindo Pharma, Mirati Therapeutics, Inc, Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Hikma Pharmaceuticals PLC and ImmunoGen, Inc.

Key Developments:

In July 2023, Genentech, Inc received approval from United States FDA for Tecentriq (atezolizumab) for adult and pediatric patients two years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).

In December 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) was approved in the United States for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.

Types Covered:

  • Monoclonal Antibodies
  • Rituximab
  • Small-Molecules
  • Amino Acids
  • Immunotoxins
  • Diphtheria toxin (DT)
  • Pseudomonas exotoxins
  • Other Types

Cancer Types Covered:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Blood Cancer
  • Gynecologic Cancer
  • Other Cancer Types

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Other Route of Administrations

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

End Users Covered:

  • Hospitals
  • Cancer and Radiation Therapy Centers
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Targeted Cancer Therapy Market, By Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
  • 5.3 Rituximab
  • 5.4 Small-Molecules
  • 5.5 Amino Acids
  • 5.6 Immunotoxins
  • 5.7 Diphtheria toxin (DT)
  • 5.8 Pseudomonas exotoxins
  • 5.9 Other Types

6 Global Targeted Cancer Therapy Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Lung Cancer
  • 6.3 Breast Cancer
  • 6.4 Colorectal Cancer
  • 6.5 Blood Cancer
  • 6.6 Gynecologic Cancer
  • 6.7 Other Cancer Types

7 Global Targeted Cancer Therapy Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Other Route of Administrations

8 Global Targeted Cancer Therapy Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacy
  • 8.3 Online Pharmacy
  • 8.4 Retail Pharmacy

9 Global Targeted Cancer Therapy Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Cancer and Radiation Therapy Centers
  • 9.4 Specialty Clinics
  • 9.5 Other End Users

10 Global Targeted Cancer Therapy Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott
  • 12.2 Pfizer Inc.
  • 12.3 Sun Pharmaceutical Industries Ltd.
  • 12.4 Amneal Pharmaceuticals LLC.
  • 12.5 Novartis AG
  • 12.6 Aurobindo Pharma
  • 12.7 Mirati Therapeutics, Inc
  • 12.8 Bayer AG
  • 12.9 Merck & Co. Inc.
  • 12.10 Bristol-Myers Squibb Company
  • 12.11 Cipla Inc.
  • 12.12 F. Hoffmann-La Roche Ltd
  • 12.13 GlaxoSmithKline plc
  • 12.14 Johnson & Johnson
  • 12.15 Hikma Pharmaceuticals PLC
  • 12.16 ImmunoGen, Inc

List of Tables

  • Table 1 Global Targeted Cancer Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Targeted Cancer Therapy Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 4 Global Targeted Cancer Therapy Market Outlook, By Rituximab (2021-2030) ($MN)
  • Table 5 Global Targeted Cancer Therapy Market Outlook, By Small-Molecules (2021-2030) ($MN)
  • Table 6 Global Targeted Cancer Therapy Market Outlook, By Amino Acids (2021-2030) ($MN)
  • Table 7 Global Targeted Cancer Therapy Market Outlook, By Immunotoxins (2021-2030) ($MN)
  • Table 8 Global Targeted Cancer Therapy Market Outlook, By Diphtheria toxin (DT) (2021-2030) ($MN)
  • Table 9 Global Targeted Cancer Therapy Market Outlook, By Pseudomonas exotoxins (2021-2030) ($MN)
  • Table 10 Global Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 11 Global Targeted Cancer Therapy Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 12 Global Targeted Cancer Therapy Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 13 Global Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 14 Global Targeted Cancer Therapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 15 Global Targeted Cancer Therapy Market Outlook, By Blood Cancer (2021-2030) ($MN)
  • Table 16 Global Targeted Cancer Therapy Market Outlook, By Gynecologic Cancer (2021-2030) ($MN)
  • Table 17 Global Targeted Cancer Therapy Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 18 Global Targeted Cancer Therapy Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 19 Global Targeted Cancer Therapy Market Outlook, By Oral (2021-2030) ($MN)
  • Table 20 Global Targeted Cancer Therapy Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 21 Global Targeted Cancer Therapy Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 22 Global Targeted Cancer Therapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 23 Global Targeted Cancer Therapy Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 24 Global Targeted Cancer Therapy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 25 Global Targeted Cancer Therapy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 26 Global Targeted Cancer Therapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Targeted Cancer Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Targeted Cancer Therapy Market Outlook, By Cancer and Radiation Therapy Centers (2021-2030) ($MN)
  • Table 29 Global Targeted Cancer Therapy Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 30 Global Targeted Cancer Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.